Autoimmune Diseases  >>  BI 695500 (rituximab biosimilar)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
BI 695500 (rituximab biosimilar) / Boehringer Ingelheim
NCT01682512 / 2011-002894-48: Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

Terminated
3
294
US, Canada, Europe, RoW
BI 695500, Rituxan®, MabThera®
Boehringer Ingelheim
Arthritis, Rheumatoid
11/15
10/16
NCT01955733 / 2013-002622-23: Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Terminated
3
91
US, Europe
BI 695500
Boehringer Ingelheim
Arthritis, Rheumatoid
11/15
11/16

Download Options